157 related articles for article (PubMed ID: 38619774)
1. Exploring the Need for Sustained GLP-1 Agonist Therapy: a Perspective on Weight Regain After Bariatric Surgery.
Chang PC; Huang YW; Huang CK; Chang TW
Obes Surg; 2024 Jun; 34(6):2259-2260. PubMed ID: 38619774
[No Abstract] [Full Text] [Related]
2. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
Jensen AB; Renström F; Aczél S; Folie P; Biraima-Steinemann M; Beuschlein F; Bilz S
Obes Surg; 2023 Apr; 33(4):1017-1025. PubMed ID: 36765019
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
[TBL] [Abstract][Full Text] [Related]
4. The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis.
Lautenbach A; Wernecke M; Huber TB; Stoll F; Wagner J; Meyhöfer SM; Meyhöfer S; Aberle J
Obes Surg; 2022 Oct; 32(10):3280-3288. PubMed ID: 35879524
[TBL] [Abstract][Full Text] [Related]
5. Poor responders after bariatric surgery - Are there second chances?
Pérez-Pevida B; Kamocka A
Endocrinol Diabetes Nutr (Engl Ed); 2018 Jan; 65(1):62-63. PubMed ID: 29221732
[No Abstract] [Full Text] [Related]
6. GLP-1 Receptor Agonists in Weight Loss and Bariatric Surgery: Balancing Efficacy and Gastrointestinal Adverse Events.
Au K; Yang W
Obes Surg; 2024 Apr; 34(4):1382-1383. PubMed ID: 38198099
[No Abstract] [Full Text] [Related]
7. Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis.
Tang T; Abbott S; le Roux CW; Wilson V; Singhal R; Bellary S; Tahrani AA
Diabetes Obes Metab; 2018 Mar; 20(3):745-748. PubMed ID: 29053203
[TBL] [Abstract][Full Text] [Related]
8. Weight Regain After Gastric Bypass: Influence of Gut Hormones.
Santo MA; Riccioppo D; Pajecki D; Kawamoto F; de Cleva R; Antonangelo L; Marçal L; Cecconello I
Obes Surg; 2016 May; 26(5):919-25. PubMed ID: 26450709
[TBL] [Abstract][Full Text] [Related]
9. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study.
Stanford FC; Alfaris N; Gomez G; Ricks ET; Shukla AP; Corey KE; Pratt JS; Pomp A; Rubino F; Aronne LJ
Surg Obes Relat Dis; 2017 Mar; 13(3):491-500. PubMed ID: 27986587
[TBL] [Abstract][Full Text] [Related]
10. Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.
Chen JH; Tang WH; Lee CH
J Med Case Rep; 2014 Sep; 8():304. PubMed ID: 25213589
[TBL] [Abstract][Full Text] [Related]
11. Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study.
Ilanga M; Heard JC; McClintic J; Lewis D; Martin G; Horn C; Khorgami Z; Richards J; Chow GS; Lim RB
Surg Endosc; 2023 Dec; 37(12):9509-9513. PubMed ID: 37700013
[TBL] [Abstract][Full Text] [Related]
12. Navigating uncharted waters: long-term implications of GLP-1 agonist use.
Sher T; Sujka J
Surg Obes Relat Dis; 2024 May; 20(5):499-500. PubMed ID: 38368200
[No Abstract] [Full Text] [Related]
13. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
Baretić M; Troskot R
Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
[TBL] [Abstract][Full Text] [Related]
14. Bariatric surgery may reduce the risk of Alzheimer's diseases through GLP-1 mediated neuroprotective effects.
Keshava HB; Mowla A; Heinberg LJ; Schauer PR; Brethauer SA; Aminian A
Med Hypotheses; 2017 Jul; 104():4-9. PubMed ID: 28673587
[TBL] [Abstract][Full Text] [Related]
15. Clinical considerations for the management of residual diabetes following bariatric surgery.
Kashyap SR; Schauer P
Diabetes Obes Metab; 2012 Sep; 14(9):773-79. PubMed ID: 22288474
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review.
Dréant A; Blanchard C; Jacobi D
Obes Surg; 2024 May; 34(5):1846-1854. PubMed ID: 38436920
[TBL] [Abstract][Full Text] [Related]
17. Initial Experience with Alternate-Day Liraglutide for Weight Regain Following Bariatric Surgery.
Rubio MA; Ramos-Leví AM
Obes Surg; 2021 Sep; 31(9):4216-4218. PubMed ID: 34212346
[No Abstract] [Full Text] [Related]
18. Current concepts in management of weight regain following bariatric surgery.
Shukla AP; He D; Saunders KH; Andrew C; Aronne LJ
Expert Rev Endocrinol Metab; 2018 Mar; 13(2):67-76. PubMed ID: 30058859
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Role of Glucagon-Like Peptide-1 Receptor Agonist-Based Therapies for Sustained Weight Loss in Post-bariatric Surgery Patients.
Dutta D; Nagendra L; Joshi A; Krishnasamy S; Sharma M; Parajuli N
Obes Surg; 2024 Jun; 34(6):2261-2262. PubMed ID: 38616240
[No Abstract] [Full Text] [Related]
20. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery.
Pajecki D; Halpern A; Cercato C; Mancini M; de Cleva R; Santo MA
Rev Col Bras Cir; 2013; 40(3):191-5. PubMed ID: 23912365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
